Performance
Stock factor profile
SUPRIYA
SUPRIYA · Healthcare · Pharmaceuticals & Biotechnology
Supriya Lifescience Ltd. supplies active pharmaceuticals ingredients (“APIs”), with a focus on research and development. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2021-12-28. The company focuses on products in various therapeutic segments, such as Antihistamine, Anti-Allergic, Vitamins, Anesthetics, Ant-Malarial and Anti-Asthmatics. The company handles chemical reactions, such as Friedel Craft’s Acylation, Claisen Condensation, Grignard Reaction, Mannich Reaction, Ritter Reaction, Eschweiler Clark reaction, Hydrogenation, Chlorination, Bromination, Decyanation, Isocyanation, Ethoxylation, Nitration, Alkylation, Reduction, Oxidation, Etherification, Chlorosulphonation, Phosphorylation, Chiral resolution, Heterocyclic chemistry, Thermal ring expansion and Protection/Deprotection. Its manufacturing facilities include delineated areas for quality check; manufacturing areas with multiple clean rooms; engineering and maintenance; warehouse; materials and finished goods stores; in-house microbiological laboratory, and functional waste treatment plant.
Equity review factors
Factor profile
Factor scores are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags and screen results for SUPRIYA are part of the Wright portfolio review.
Run your free portfolio reviewFundamental snapshot
Fundamentals at a glance
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.